Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria

Expert Opinion on Investigational Drugs

Volumn 19, Issue 12, 2010, Pages 1591-1602

  Minder, Elisabeth I ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

a MSH analogs; afamelanotide; MC1R polymorphism; melanocortin receptor; phototoxicity; protoporphyria; treatment

Indexed keywords

ACETYLCYSTEINE; AFAMELANOTIDE; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; ASCORBIC ACID; BETA CAROTENE; CANTHAXANTHIN; CYSTEINE; DIHYDROXYACETONE; LAWSONE; MELANIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; PLACEBO; PROOPIOMELANOCORTIN; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; CAUCASIAN; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG RECEPTOR BINDING; DRUG SAFETY; EDEMA; ERYTHEMA; ERYTHROPOIETIC PROTOPORPHYRIA; FLUSHING; GENE THERAPY; GENOTYPE; HEADACHE; HUMAN; MAST CELL; MELANOMA; NAUSEA; NONHUMAN; PAIN; PETECHIA; PHENOTYPE; PHOTOTOXICITY; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN DEFECT; SKIN INFLAMMATION; SKIN PROTECTION; SKIN TOXICITY; SUN EXPOSURE; SUNLIGHT; SUNLIGHT PROTECTION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; VOMITING; X CHROMOSOME LINKED DISORDER;

ADMINISTRATION, CUTANEOUS; ALPHA-MSH; ANIMALS; CLINICAL TRIALS AS TOPIC; DERMATITIS, PHOTOTOXIC; HUMANS; PROTOPORPHYRIA, ERYTHROPOIETIC; SKIN;

EID: 78649496186     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.535515     Document Type: Review

References (104)

1. Anderson K, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaugrand M, Sly WS, Valle D, editors, The metabolic and molecular basis of inherited disease. 8th edition. McGraw-Hill, New York; 2001. p. 2991-3062
2. Schneider-Yin X, Gouya L, Meier-Weinand A, et al. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 2000;159:719-25
3. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Ophanet J Rare Dis 2009;4:19
4. Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 1984;48:105-17
5. Whatley SD, Mason NG, Holme SA, et al. Molecular epidemiology of erythropoietic protoporphyria in the U. K. Br J Dermatol 2010;162:642-6
6. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002;30:27-8
7. Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008;83:408-14
8. Piomelli S, Lamola AA, Poh-Fitzpatrick MF, et al. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest 1975;56:1519-27
9. Brun A, Western A, Malik Z, Sandberg S. Erythropoietic protoporphyria: photodynamic transfer of protoporphyrin from intact erythrocytes to other cells. Photochem Photobiol 1990;51:573-7
10. Ibrahim GW, Watson CJ. Enterohepatic circulation and conversion of protoporphyrin to bile pigment in man. Proc Soc Exp Biol Med 1968;127:890-5
11. Afonso SG, Enriquez DS, Batlle AM. The photodynamic and non-photodynamic actions of porphyrins. Braz J Med Biol Res 1999;32:255-66
12. Magnus IA, Jarrett A, Prankerd TA, Rimington C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961;2:448-51
13. Bagdonas S, Ma LW, Iani V, et al. Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 2000;72:186-92
14. Goldstein BD, Harber LC. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest 1972;51:892-902
15. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981;77:13-9
16. Parrish JA, Rosen CF, Gange RW. Therapeutic uses of light. Ann NY Acad Sci 1985;453:354-64
17. Timonen K, Kariniemi AL, Niemi KM, et al. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol 2000;43:489-97
18. Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 1989;46:671-85
19. Lim HW. Pathogenesis of photosensitivity in the cutaneous porphyrias. J Invest Dermatol 2005;124:xvi-vii
20. Rufener EA. ". and found no shade". Coping processes of patients with erythropoietic protoporphyria. Psychother Psychosom Med Psychol 1992;42:339-48
21. Rufener EA. Erythropoietic protoporphyria: a study of its psychosocial aspects. Br J Dermatol 1987;116:703-8
22. Jong CT, Finlay AY, Pearse AD, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008;159:192-7
23. Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008;14:1340-6
24. Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009;55:84-97
25. Corbett MF, Herxheimer A, Magnus IA, et al. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977;97:655-62
26. Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the U. K.: clinical features and effect on quality of life. Br J Dermatol 2006;155:574-81
27. Wahlin S, Floderus Y, Stal P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2010: published online 13 March 2010, DOI: 10.1111/j.1365-2796.2010. 02236.x
28. Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995;132:956-63
29. Murphy GM, Hawk JL. Erythropoietic protoporphyria advances today, with a special tribute to the late Professor Ian Magnus. Br J Dermatol 2006;155:501-3
30. Rufener EA. Schattenspringen; Krankheitsanpassung bei Menschen mit einer erythropoetischen Protoporphyrie. 1-386. 1990. Universitat Zurich, Philosophische Fakultat I. (Thesis/ Dissertation)
31. Pawliuk R, Tighe R, Wise RJ, et al. Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. J Invest Dermatol 2005;124:256-62
32. Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999;5:768-73
33. Poh-Fitzpatrick MB, Wang X, Anderson KE, et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 2002;46:861-6
34. Rand EB, Bunin N, Cochran W, et al. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006;118:e1896-9
35. Wahlin S, Aschan J, Bjornstedt M, et al. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007;46:174-9
36. Crombie IK. Racial differences in melanoma incidence. Br J Cancer 1979;40:185-93
37. Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979;40:774-81
38. MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91
39. Healy E, Jordan SA, Budd PS, et al. Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 2001;10:2397-402
40. Makova K, Norton H. Worldwide polymorphism at the MC1R locus and normal pigmentation variation in humans. Peptides 2005;26:1901-8
41. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005;571:133-52
42. Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67-90
43. Sturm RA, Duffy DL, Box NF, et al. Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann NY Acad Sci 2003;994:348-58
44. Ha T, Naysmith L, Waterston K, et al. Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype. Ann NY Acad Sci 2003;994:339-47
45. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30
46. Nordlund JJ, Boissy RE, Haering VJ, et al. The pigmentary system: physiology and pathophysiology. 2nd edition. Blackwell Publishing Ltd, Malden, Massachusetts; 2006
47. Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005;280:5795-802
48. Song X, Mosby N, Yang J, et al. alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009;22:809-18
49. Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996;63:1-10
50. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007;128:853-64
51. Barsh G, Attardi LD. A healthy tan? N Engl J Med 2007;356:2208-10
52. Khaled M, Larribere L, Bille K, et al. Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem 2002;277:33690-7
53. Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol 2006;126:1966-75
54. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86
55. April CS, Barsh GS. Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet 2007;3:e9
56. Robinson S, Dixon S, August S, et al. Protection against UVR Involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo. J Invest Dermatol 2010;130:1904-13
57. Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res 2009;22:635-44
58. Dong L, Wen J, Pier E, et al. Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res 2010;70:3547-56
59. Kokot A, Metze D, Mouchet N, et al. alpha-Melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 2009;150:3197-206
60. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006;27:736-49
61. Wikberg JE. Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol 1999;375:295-310
62. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006;27:921-30
63. Kadekaro AL, Wakamatsu K, Ito S, Abdel-Malek ZA. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006;11:2157-73
64. Gantz I, Konda Y, Tashiro T, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50
65. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-9
66. Spencer JD, Schallreuter KU. Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/ melanocortin-4 receptor signaling. Endocrinology 2009;150:1250-8
67. Beaumont KA, Shekar SN, Newton RA, et al. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007;16:2249-60
68. Beaumont KA, Shekar SN, Cook AL, et al. Red hair is the null phenotype of MC1R. Hum Mutat 2008;29:E88-94
69. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-7
70. Ghanem G, Verstegen J, Libert A, et al. Alpha-melanocyte-stimulating hormone immunoreactivity in human melanoma metastases extracts. Pigment Cell Res 1989;2:519-23
71. Ghanem G, Verstegen J, De Rijcke S, et al. Studies on factors influencing human plasma alpha-MSH. Anticancer Res 1989;9:1691-6
72. Nagahama M, Funasaka Y, Fernandez-Frez ML, et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 1998;138:981-5
73. Sheppard JR, Koestler TP, Corwin SP, et al. Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. Nature 1984;308:544-7
74. Lunec J, Pieron C, Thody AJ. MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma. Melanoma Res 1992;2:5-12
75. Bennett DC, Dexter TJ, Ormerod EJ, Hart IR. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986;46:3239-44
76. Abdel-Malek Z, Swope VB, Suzuki I, et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 1995;92:1789-93
77. Murata J, Ayukawa K, Ogasawara M, et al. Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93
78. Eves P, Haycock J, Layton C, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003;89:2004-15
79. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006;27:444-52
80. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505
81. Osawa M, Egawa G, Mak SS, et al. Molecular characterization of melanocyte stem cells in their niche. Development 2005;132:5589-99
82. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37
83. Ackermann J, Frutschi M, Kaloulis K, et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005;65:4005-11
84. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33
85. Jiang J, Sharma SD, Nakamura S, et al. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995;8:314-23
86. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997;18:259-69
87. Bhardwaj R, Hadley ME, Dorr RT, et al. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I. Pharm Res 2000;17:593-9
88. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980;77:5754-8
89. Frandberg PA, Muceniece R, Prusis P, et al. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochem Biophys Res Commun 1994;202:1266-71
90. Yang Y, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997;272:23000-10
91. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J 2006;20:1561-3
92. Kadekaro AL, Kavanagh R, Kanto H, et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005;65:4292-9
93. Newton RA, Smit SE, Barnes CC, et al. Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells1. Peptides 2005;26:1818-24
94. Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN®, [Nle4, D-Phe7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006;27:388-94
95. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78
96. Minder EI. Afamelanotide. Drugs Future 2010;35:365-72
97. Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-7
98. Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009;85:1434-9
99. Minder EI, Harms J, Lautenschlager S, et al. A double-blind, randomized, controlled Phase III trial of afamelanotide (an alpha-MSH analogue) in erythropoietic protoporphyria (EPP) - preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP [abstract]. http://www.svls.se/cs-media/xyz/bz81final. pdf [Last accessed 29 October 2010]
100. Minder EI, Schneider-Yin X, Minder CE. Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal. Health Qual Life Outcomes 2010;8:60
101. Preliminary results in Clinuvel's Phase III porphyria trial. Melbourne, Australia: Clinuvel Pharmaceuticals Ltd. 2009. Available from: http://clinuvel. com/resources/cmsfiles/pdf/ 20091221EPPPrelim.pdf [Last accessed 30 October 2010]
102. Clinuvel reports positive results in phase III porphria (EPP) clinical trial. Melbourne, Australia: Clinuvel Pharmaceuticals Ltd. 2020. Available from: http://clinuvel. com/resources/cmsfiles/pdf/ 20100713CUV017Results.pdf [Last accessed 22 October 2010]
103. Wikberg JES. Melanocortin receptors: new oportunities in drug discovery. Expert Opin Ther Pat 2001;11:61-76
104. Schioth HB, Chhajlani V, Muceniece R, et al. Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 1996;59:797-801